ArticleCancer cell2022
Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts.
Erratum issuedOpen access · hybridAbstract read
In one paragraph
Article in Cancer cell, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 51 papers.
0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
8.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 85 citations in OpenAlex.
- Radiotherapy With a 12-Gene Expression Assay for Ductal Carcinoma In Situ: A Randomized Clinical Trial.JAMA oncology · 2025Trial
- Integrated Multi-Omics Reveals Cellular States and Microenvironmental Remodeling in Coexisting DCIS and IDC.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Identification of cycling regulatory T cell precursors as conductors of immune escape during breast carcinoma progression.Cancer cell · 2026Article
- Identifying clinically relevant cell state interactions in the tumor microenvironment of IDH-mutant gliomas using CSI-TME.Molecular systems biology · 2026Article
- Transcriptome predictors of second breast events in ductal carcinoma in situ: a case‒control study including Black and White women.Breast cancer research : BCR · 2026Article
- Rank signaling drives basal cell-lineage infidelity leading to mammary tumorigenesis.Nature communications · 2026Article
- Metabolic plasticity of sphingolipids governs cancer cell fitness in acidic tumor ecosystems.bioRxiv : the preprint server for biology · 2026Article
- PCSK5M452I Is a Recessive Hypomorph Exclusive to MCF10DCIS.com Cells.Molecular cancer research : MCR · 2026Article
- Review
- Spatially Discontinuous Mutation Topographies in Ductal Carcinoma In Situ Reveal Noncompetitive Growth Dynamics.Cancer research · 2025Article
- Circulating tumor cells as predictive biomarkers in the risk stratification of DCIS: Evidence of early dissemination.Science advances · 2025Article
- Mutational landscape of pure ductal carcinoma in situ and associations with disease prognosis and response to radiotherapy.Breast cancer research : BCR · 2025Article
- Cancer outcomes in women without upfront surgery for ductal carcinoma in situ: observational cohort study.BMJ (Clinical research ed.) · 2025Observational
- Single-cell tumor microenvironment profiling informs a circulating proteome test for the interception of malignant transformation in NF1 nerve sheath tumors.Research square · 2025Article
- Eco-Evolutionary Guided Pathomic Analysis Detects Biomarkers to Predict Ductal Carcinoma In Situ Upstaging.Cancer research · 2025Article
- Deep learning for predicting invasive recurrence of ductal carcinoma in situ: leveraging histopathology images and clinical features.EBioMedicine · 2025Article
- Exploring the tumor microenvironment of breast cancer to develop a prognostic model and predict immunotherapy responses.Scientific reports · 2025Article
- Multimodal data integration in early-stage breast cancer.Breast (Edinburgh, Scotland) · 2025Review
- B cells and energy metabolism in HER2-positive DCIS: insights into breast cancer progression from spatial-omics analyses.Breast cancer research : BCR · 2025Article
- Evolutionary measures show that recurrence of DCIS is distinct from progression to breast cancer.Breast cancer research : BCR · 2025Article
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
52 authors at 20 institutions in 3 countries.
Siri H StrandDepartment of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Molecular Medicine, Aarhus University Hospital, 8200 Aarhus N, Denmark.
Belén Rivero-GutiérrezDepartment of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Kathleen E HoulahanStanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.
Jose A SeoaneStanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Vall d'Hebron Institute of Oncology, 08035 Barcelona, Spain.
Lorraine M KingDepartment of Surgery, Duke University School of Medicine, Durham, NC 27708, USA.
Tyler RisomDepartment of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Lunden A SimpsonDepartment of Surgery, Duke University School of Medicine, Durham, NC 27708, USA.
Sujay VennamDepartment of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Aziz KhanStanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.
Luis CisnerosSchool of Life Sciences, Arizona State University, Tempe, AZ 85281, USA.
Timothy HardmanDepartment of Surgery, Duke University School of Medicine, Durham, NC 27708, USA.
Bryan HarmonDepartment of Pathology, Montefiore Medical Center, Bronx, NY 10467, USA; TBCRC Loco-Regional Working Group, Baltimore, MD 21287, USA.
Fergus CouchTBCRC Loco-Regional Working Group, Baltimore, MD 21287, USA; Department of Pathology, Mayo Clinic, Rochester, MN 55902, USA.
Kristalyn GallagherTBCRC Loco-Regional Working Group, Baltimore, MD 21287, USA; Department of Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Mark KilgoreTBCRC Loco-Regional Working Group, Baltimore, MD 21287, USA; Department of Pathology, University of Washington, Seattle, WA 98195, USA.
Shi WeiTBCRC Loco-Regional Working Group, Baltimore, MD 21287, USA; Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Angela DeMicheleTBCRC Loco-Regional Working Group, Baltimore, MD 21287, USA; Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Tari KingTBCRC Loco-Regional Working Group, Baltimore, MD 21287, USA; Breast Oncology Program, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Surgery, Brigham and Women's Hospital, Boston, MA 02115, USA.
Priscilla F McAuliffeTBCRC Loco-Regional Working Group, Baltimore, MD 21287, USA; Department of Surgery, University of Pittsburgh, Pittsburgh, PA 15213, USA.
Julie NangiaTBCRC Loco-Regional Working Group, Baltimore, MD 21287, USA; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston TX 77030, USA.
Joanna LeeTBCRC Loco-Regional Working Group, Baltimore, MD 21287, USA; Department of Surgery, MD Anderson Cancer Center, Houston, TX 77030, USA.
Jennifer TsengTBCRC Loco-Regional Working Group, Baltimore, MD 21287, USA; Department of Surgery, University of Chicago, Chicago, IL 60637, USA.
Anna Maria StornioloTBCRC Loco-Regional Working Group, Baltimore, MD 21287, USA; Department of Medicine, Indiana University, Indianapolis, IN 46202, USA.
Alastair M ThompsonTBCRC Loco-Regional Working Group, Baltimore, MD 21287, USA; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston TX 77030, USA; Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA.
Gaorav P GuptaTBCRC Loco-Regional Working Group, Baltimore, MD 21287, USA; Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Robyn BurnsTBCRC Loco-Regional Working Group, Baltimore, MD 21287, USA; TBCRC, The EMMES Corporation, Rockville, MD 20850, USA.
Deborah J VeisDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63108, USA; Departments of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO 63108, USA.
Katherine DeSchryverDepartments of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO 63108, USA.
Chunfang ZhuDepartment of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Magdalena MatusiakDepartment of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Jason WangDepartment of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Shirley X ZhuDepartment of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Jen TappendenDepartment of Surgery, Washington University School of Medicine, St. Louis, MO 63110, USA.
Daisy Yi DingDepartment of Biomedical Data Science, Stanford University, Stanford, CA 94305, USA.
Dadong ZhangDuke Cancer Institute, Duke University School of Medicine, Durham, NC 27708, USA.
Jingqin LuoDepartment of Surgery, Washington University School of Medicine, St. Louis, MO 63110, USA.
Shu JiangDepartment of Surgery, Washington University School of Medicine, St. Louis, MO 63110, USA.
Sushama VarmaDepartment of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Lauren AndersonDepartment of Surgery, Duke University School of Medicine, Durham, NC 27708, USA.
Cody StraubDepartment of Surgery, Duke University School of Medicine, Durham, NC 27708, USA.
Sucheta SrivastavaDepartment of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Christina CurtisStanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Medicine and Genetics, Stanford University, Stanford, CA 94305, USA.
Rob TibshiraniDepartment of Biomedical Data Science, Stanford University, Stanford, CA 94305, USA; Department of Statistics, Stanford University, Stanford, CA 94305, USA.
Robert Michael AngeloDepartment of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Allison HallDepartment of Pathology, Duke University School of Medicine, Durham, NC 27708, USA.
Kouros OwzarDuke Cancer Institute, Duke University School of Medicine, Durham, NC 27708, USA; Department of Biostatistics & Bioinformatics, Duke University School of Medicine, Durham, NC 27708, USA.
Kornelia PolyakDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Carlo MaleySchool of Life Sciences, Arizona State University, Tempe, AZ 85281, USA.
Jeffrey R MarksDepartment of Surgery, Duke University School of Medicine, Durham, NC 27708, USA.
Graham A ColditzDepartment of Surgery, Washington University School of Medicine, St. Louis, MO 63110, USA.
E Shelley HwangDepartment of Surgery, Duke University School of Medicine, Durham, NC 27708, USA. Electronic address: shelley.hwang@duke.edu.
Robert B WestDepartment of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA. Electronic address: rbwest@stanford.edu.
Stanford University · USDuke University · USWashington University in St. Louis · USArizona State University · USBaylor College of Medicine · USUniversity of North Carolina at Chapel Hill · USAarhus University Hospital · DKBrigham and Women's Hospital · USDana-Farber Cancer Institute · USEmmes (United States) · USIndiana University – Purdue University Indianapolis · USMayo Clinic · USMontefiore Medical Center · USStanford Medicine · USThe University of Texas MD Anderson Cancer Center · USUniversity of Alabama at Birmingham · USUniversity of Chicago · USUniversity of Pennsylvania · USUniversity of Pittsburgh · USUniversity of Washington · US
Funding
Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI JOHN N. NORTON · 1985 to 2026
$174.8MWashington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI AIMEE S JAMES · 2001 to 2026
$128.0MMolecular, Cellular and Tissue Characterization UnitU2CCA233254 · NCI · DUKE UNIVERSITY · PI HWANG, E.SHELLEY, MALEY, CARLO · 2018 to 2023
$11.4MThe Role of the Microbiome in Cancer Suppression and Susceptibility Across SpeciesU54CA217376 · NCI · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI MALEY, CARLO · 2018 to 2022
$8.6MGenomic and Morphologic Predictor of High-Risk DCISR01CA193694 · NCI · STANFORD UNIVERSITY · PI WEST, ROBERT B · 2016 to 2020
$3.5MBreast Cancer Detection ConsortiumU01CA214183 · NCI · DUKE UNIVERSITY · PI MARKS, JEFFREY R., TANG, CHA-MEI · 2016 to 2021
$2.4M(PQC3) Genomic Diversity and Microenvironment as Drivers of Metastasis in DCISR01CA185138 · NCI · DUKE UNIVERSITY · PI HWANG, E.SHELLEY, MALEY, CARLO · 2014 to 2017
$2.0MNCI NIH HHS P30 CA014236NCI NIH HHS P30 CA091842NCI NIH HHS R01 CA185138NCI NIH HHS R01 CA193694NCI NIH HHS U01 CA214183NCI NIH HHS U2C CA233254NCI NIH HHS U54 CA217376
Abstract
Ductal carcinoma in situ (DCIS) is the most common precursor of invasive breast cancer (IBC), with variable propensity for progression. We perform multiscale, integrated molecular profiling of DCIS with clinical outcomes by analyzing 774 DCIS samples from 542 patients with 7.3 years median follow-up from the Translational Breast Cancer Research Consortium 038 study and the Resource of Archival Breast Tissue cohorts. We identify 812 genes associated with ipsilateral recurrence within 5 years from treatment and develop a classifier that predicts DCIS or IBC recurrence in both cohorts. Pathways associated with recurrence include proliferation, immune response, and metabolism. Distinct stromal expression patterns and immune cell compositions are identified. Our multiscale approach employed in situ methods to generate a spatially resolved atlas of breast precancers, where complementary modalities can be directly compared and correlated with conventional pathology findings, disease states, and clinical outcome.
Indexed as
Breast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, Intraductal, NoninfiltratingBiomarkersBiomarkers, TumorDisease ProgressionFemaleHumansBiomarkersBiomarkers, Tumorbreastclassifierductal carcinoma in situmultiplex immunohistochemistryprecancerprognosisprogressionRNA gene expression profilingtumor microenvironmentwhole genome sequencing
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.